MBX Surges As Phase II Data Show Competitive Profile For Canvuparatide

Hypoparathyroidism Drug Will Move Into Phase III In 2026

 
• By Mandy Jackson
  
HP patients treated with MBX's canvuparatide reduced their daily calcium pill burden (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D